Sandoz signs agreement with Pear Therapeutics to develop and commercialize prescription digital therapeutics for patients with substance use disorder and opioid use disorders

  • Deal includes reSET®, cleared by FDA for treatment of patients with Substance Use Disorder, and reSET-O™, potential treatment pending FDA clearance for patients with Opioid Use Disorder treated with buprenorphine 
  • Combines Sandoz expertise in launching / commercializing treatments with Pear’s expertise in developing prescription digital therapeutics 
  • Sandoz and Novartis continue to embrace emerging digital technologies to enhance R&D and deliver better outcomes for patients

…

/by

Sandoz signs agreement with Pear Therapeutics to develop and commercialize prescription digital therapeutics for patients with substance use disorder and opioid use disorders

  • Deal includes reSET®, cleared by FDA for treatment of patients with Substance Use Disorder, and reSET-O™, potential treatment pending FDA clearance for patients with Opioid Use Disorder treated with buprenorphine 
  • Combines Sandoz expertise in launching / commercializing treatments with Pear’s expertise in developing prescription digital therapeutics 
  • Sandoz and Novartis continue to embrace emerging digital technologies to enhance R&D and deliver better outcomes for patients

…

/by

Sandoz outlines plans for next Healthcare Access Challenge (HACk), to support local digital innovation

  • Sandoz White Paper outlines importance of digital solutions to specific local healthcare problems, as part of approach to increasing access to healthcare
  • Publication, which coincides with World Health Day 2018, outlines plans for expanded competition to “reimagine access to healthcare”
  • Upcoming HACk will draw strongly on learnings of past year; publication summarizes progress to date on three winning 2017 projects

Holzkirchen, April 7, 2018 – Sandoz today announces its continued commitment to improving …

/by

Sandoz outlines plans for next Healthcare Access Challenge (HACk), to support local digital innovation

  • Sandoz White Paper outlines importance of digital solutions to specific local healthcare problems, as part of approach to increasing access to healthcare
  • Publication, which coincides with World Health Day 2018, outlines plans for expanded competition to “reimagine access to healthcare”
  • Upcoming HACk will draw strongly on learnings of past year; publication summarizes progress to date on three winning 2017 projects

Holzkirchen, April 7, 2018 – Sandoz today announces its continued commitment to improving …

/by

Sandoz receives positive CHMP opinion for proposed biosimilar infliximab

  • Sandoz is seeking approval of biosimilar infliximab for use in all indications of its reference medicine across gastroenterology, rheumatology and dermatology
  • Positive opinion is based on comprehensive clinical and non-clinical data that is expected to confirm that Sandoz biosimilar infliximab matches the reference medicine
  • This recommendation marks the third CHMP positive opinion granted for a Sandoz biosimilar in 12 months following Erelzi® and Rixathon®; Sandoz is on track to launch several biosimilars of major oncology …
/by

Sandoz receives positive CHMP opinion for proposed biosimilar infliximab

  • Sandoz is seeking approval of biosimilar infliximab for use in all indications of its reference medicine across gastroenterology, rheumatology and dermatology
  • Positive opinion is based on comprehensive clinical and non-clinical data that is expected to confirm that Sandoz biosimilar infliximab matches the reference medicine
  • This recommendation marks the third CHMP positive opinion granted for a Sandoz biosimilar in 12 months following Erelzi® and Rixathon®; Sandoz is on track to launch several biosimilars of major oncology …
/by

Sandoz announces US FDA approval and launch of Glatopa® 40 mg/mL three times-a-week generic option for relapsing forms of multiple sclerosis

  • Glatopa® 40 mg/mL is a fully substitutable, AP-rated generic version of Copaxone®* (glatiramer acetate injection) 40 mg/mL
  • Glatopa 40 mg/mL, along with Glatopa® 20 mg/mL, which was launched in the US in June 2015, will offer patients a complete range of dosing options
  • A full range of patient support services for Glatopa® is available through GlatopaCare®

Holzkirchen, February 13, 2018 – Sandoz, a Novartis division, today announced the US FDA approval …

/by

Sandoz certified as Top Employer Europe 2018

  • Sandoz has been officially certified by the Top Employers Institute for its exceptional employee offerings in Europe and Russia
  • The annual, international research undertaken by the Top Employers Institute recognizes leading employers around the world
  • This exclusive certification underlines Sandoz´ commitment to attract and retain the best people from the industry

Holzkirchen, February 1, 2018 – Sandoz, a Novartis division, is proud to announce that it has officially been certified “TOP Employer Europe 2018” for …

/by

Novartis delivered good operational performance and landmark innovation in 2017, entering our next growth phase

  • Full year sales grew 2% (cc, +1% USD) as strong performance of our growth drivers, including Cosentyx and Entresto, more than offset Gleevec/Glivec generic erosion:
    • Cosentyx grew to USD 2.1 billion in 2017, USD 615 million in Q4
    • Entresto grew to USD 507 million in 2017, USD 185 million in Q4
    • Oncology excluding Gleevec/Glivec grew 10% (cc), with 13% (cc) growth in Q4
  • Full year 2017 core[1] operating income was broadly in line with prior year (0% cc …
/by

Sandoz announces exclusive global collaboration with Biocon on next-generation biosimilars

  • Collaboration aims to help patients worldwide gain access to a range of high-quality, affordable immunology and oncology biologics
  • Partnership will be an important part of Sandoz and Biocon strategy to address the next wave of biosimilar opportunities globally
  • Collaboration will leverage combined strengths of development, manufacturing and commercialization of biosimilars
  • Partnership provides foundation for expansion of portfolio 

Holzkirchen, 18 January 2018 – Sandoz, a Novartis …

/by